Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders.
Alzheimer’s disease
Basal forebrain cholinergic progenitor cells
Neurological disorder
Stem cells
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
16
11
2017
accepted:
16
02
2018
pubmed:
20
3
2018
medline:
2
4
2019
entrez:
18
3
2018
Statut:
ppublish
Résumé
A neurological disorder is any disorder or abnormality in the nervous system. Among different neurological disorders, Alzheimer's disease (AD) is recognized as the sixth leading cause of death globally. Considerable research has been conducted to find pioneer treatments for this devastating disorder among which cell therapy has attracted remarkable attentions over the last decade. Up to now, targeted differentiation into specific desirable cell types has remained a major obstacle to clinical application of cell therapy. Also, potential risks including uncontrolled growth of stem cells could be disastrous. In our novel protocol, we used basal forebrain cholinergic progenitor cells (BFCN) derived from human chorion-derived mesenchymal stem cells (hC-MSCs) which made it possible to obtain high-quality population of cholinergic neurons and in vivo in much shorter time period than previous established methods. Remarkably, the transplanted progenitors fully differentiated to cholinergic neurons which in turn integrated in higher cortical networks of host brains, resulting in significant improvement in cognitive assessments. This method may have profound implications in cell therapies for any other neurodegenerative disorders. Graphical Abstract ᅟ.
Identifiants
pubmed: 29549645
doi: 10.1007/s12035-018-0968-1
pii: 10.1007/s12035-018-0968-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-318Commentaires et corrections
Type : ErratumIn
Références
Mol Ther. 2004 May;9(5):682-8
pubmed: 15120329
Nat Biotechnol. 2005 Jul;23(7):862-71
pubmed: 16003375
Brain Res Rev. 2006 Sep;52(2):244-56
pubmed: 16644019
Nat Med. 2006 Nov;12(11):1259-68
pubmed: 17057709
Nature. 2007 Nov 29;450(7170):717-20
pubmed: 18046410
Cell Transplant. 2008;17(4):383-95
pubmed: 18522241
PLoS Med. 2009 Feb 17;6(2):e1000029
pubmed: 19226183
Stroke. 2010 Jan;41(1):153-9
pubmed: 19940279
Nat Neurosci. 2010 Jul;13(7):812-8
pubmed: 20581818
Nat Rev Neurol. 2011 Mar;7(3):137-52
pubmed: 21304480
Stem Cells. 2011 May;29(5):802-11
pubmed: 21381151
Cell Death Differ. 2012 Apr;19(4):680-91
pubmed: 22015609
Nature. 2011 Nov 06;480(7378):547-51
pubmed: 22056989
Cell Stem Cell. 2013 Apr 4;12(4):385-6
pubmed: 23561437
Nat Biotechnol. 2013 May;31(5):440-7
pubmed: 23604284
Int J Stroke. 2014 Apr;9(3):381-6
pubmed: 23692637
Prog Neurobiol. 2014 Apr;115:92-115
pubmed: 24333397
Mol Neurodegener. 2014 Jan 08;9:3
pubmed: 24401693
Nat Rev Genet. 2014 Feb;15(2):82-92
pubmed: 24434846
Mol Neurobiol. 2014 Oct;50(2):423-37
pubmed: 24481678
Science. 2014 Aug 22;345(6199):1247391
pubmed: 25146295
J Mol Neurosci. 2015 Jul;56(3):708-21
pubmed: 25634726
Neuroscience. 2015 Apr 16;291:81-92
pubmed: 25681520
Mol Neurobiol. 2016 Apr;53(3):1862-1872
pubmed: 25790953
Stem Cells Transl Med. 2015 Jul;4(7):841-51
pubmed: 26025980
Cell Death Dis. 2015 Jun 18;6:e1789
pubmed: 26086962
Nature. 2015 Jul 23;523(7561):431-436
pubmed: 26176913
Cell Stem Cell. 2015 Oct 1;17(4):385-95
pubmed: 26431181
Stem Cell Reports. 2015 Nov 10;5(5):776-790
pubmed: 26489896
Cell Stem Cell. 2016 Feb 4;18(2):174-88
pubmed: 26849304
Neuroscientist. 2017 Jun;23(3):314-329
pubmed: 27624848
J Pharmacol Toxicol Methods. 2017 Mar - Apr;84:44-50
pubmed: 27746217
Psychiatry Investig. 2016 Nov;13(6):583-589
pubmed: 27909447
Small GTPases. 2017 Jan 26;:1-7
pubmed: 28125332
Stem Cell Reports. 2017 Mar 14;8(3):673-684
pubmed: 28262544
Trends Biotechnol. 2017 Oct;35(10):937-953
pubmed: 28666544